17 completed. 17 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Typhoid Fever: new trials by email Literature Review of Typhoid Fever trials Research Report on Typhoid Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever Levofloxacin, ciprofloxacin - Typhoid, Fever | Phase 2 | Completed | Avicenna Medical College Lahore | 360 | 2025-02-07 | 2025-09-02 |
| Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM - Typhoid | Phase 2 | Completed | Kathleen Neuzil | 147 | 2024-08-17 | 2026-06-03 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV) - Typhoid | Phase 2 | Completed | University of Maryland, Baltimore | 251 | 2018-12-03 | 2025-05-30 |
| Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution - Typhoid | Phase 2 | Completed | International Vaccine Institute | 285 | 2018-04-18 | 2021-08-27 |
| Vaccines Against Salmonella Typhi Vi-TCV, Vi-PS Vaccine, Control (Men ACWY) - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 112 | 2015-09-01 | 2022-07-05 |
| Understanding Typhoid Disease After Vaccination Vaccine placebo (excipients only), Ty21a, M10ZH09 vaccine - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 99 | 2011-10-07 | 2023-05-06 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine - Typhoid Fever | Phase 2 | Completed | Novartis | 120 | 2011-10-01 | 2014-04-10 |
| Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults NVGH Vi-CRM197 - Typhoid Fever | Phase 2 | Completed | Novartis | 51 | 2011-10-01 | 2014-03-24 |
| Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine - Typhoid Fever | Phase 2 | Completed | Novartis | 200 | 2011-03-01 | 2014-05-01 |
| Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg - Typhoid Fever | Phase 2 | Completed | Novartis | 88 | 2010-10-01 | 2014-01-17 |
| Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3) - Typhoid | Phase 2 | Completed | Emergent BioSolutions | 187 | 2008-05-01 | 2024-04-09 |
| Studies of Immune Responses to Orally Administered Vaccines in Developing Country Placebo, Control, Zinc Sulphate - Cholera, Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 1016 | 2008-02-01 | 2011-07-12 |
| Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Ty800 (Salmonella typhi) Oral Vaccine - Typhoid Fever | Phase 2 | Completed | Avant Immunotherapeutics | 180 | 2007-07-01 | 2008-07-02 |
| Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants Vi-rEPA conjugate vaccine for typhoid fever, Hib-TT, DTP - Typhoid Fever | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 301 | 2006-07-01 | 2012-06-27 |
| TY800 Dose Escalation (Typhoid) Ty800, Placebo - Typhoid and Paratyphoid Fevers | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 47 | 2006-02-01 | 2011-06-10 |
Cholera (1) · Fever (1) · Paratyphoid Fever (1)
Bacterial Infections (17) · Bacterial Infections and Mycoses (17) · Enterobacteriaceae Infections (17) · Gram-Negative Bacterial Infections (17) · Infections (17) · Salmonella Infections (17) · Body Temperature Changes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Vibrio Infections (1)
Vaccines (3) · 13-valent pneumococcal vaccine (2) · Pneumococcal Vaccines (2) · Polysaccharides (2) · Vi polysaccharide vaccine, typhoid (2) · Albendazole (1) · Arsenic (1) · Ciprofloxacin (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1) · Levofloxacin (1) · Meningococcal Vaccines (1) · Poliovirus Vaccine, Inactivated (1) · Ty21a typhoid vaccine (1) · Zinc Sulfate (1) · secnidazole (1)
Novartis (4) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · University of Oxford (2) · Avant Immunotherapeutics (1) · Avicenna Medical College Lahore (1) · Emergent BioSolutions (1) · EuBiologics Co.,Ltd (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · International Vaccine Institute (1) · Kathleen Neuzil (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Maryland, Baltimore (1)
Philippines (3) · United States (3) · Bangladesh (2) · Belgium (2) · Burkina Faso (2) · Pakistan (2) · United Kingdom (2) · India (1) · Vietnam (1)
Andrew J Pollard (1) · Andrew J Pollard, FRCPCH, PhD (1) · Clark McKeever, MD (1) · Farhana Khanam, MPhil, PhD (1) · Firdausi Qadri, PhD (1) · Laurens Matthew, MD (1) · Maria Rosario Capeding, MD (1) · Maria Rosario Z Capeding, MD (1) · Pierre Van Damme, MD (1) · Professor Aneela Zareen, MBBS FCPS (1) · Stephen Lockhart, DM (1)
PMID 24290843, PMID 20188175, PMID 21980445, PMID 27533046, PMID 28965718, PMID 30845330, PMID 31585725, PMID 31877141, PMID 33150320, PMID 36774331, PMID 36875126, PMID 37402153, PMID 40446606